A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.

Trial Profile

A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs ADX-10059 (Primary)
  • Indications Anxiety
  • Focus Therapeutic Use
  • Sponsors Addex Therapeutics
  • Most Recent Events

    • 03 Jan 2008 Status changed from in progress to completed
    • 03 Jan 2008 Primary endpoint not met; data reported by Addex in a company media release.
    • 24 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top